

Curriculum Vitae

Personal Data

Title	Professor, Dr. rer. nat.
First name	Ralph
Name	Schermuly
Current position	Professur "Pulmonary Pharmacotherapy"
Current institution(s)/site(s), country	Justus-Liebig-Universität Gießen, Medizinische Klinik II, Germany
Identifiers/ORCID	https://orcid.org/0000-0002-5167-6970

Qualifications and Career

Stages	Periods and Details
Degree programme	Studies of Biology, Justus Liebig University Giessen, 1987 – 1993, Gießen, Germany
Doctorate	Doctorate Biology, Justus Liebig University Giessen, 1996, Gießen, Germany
Habilitation	Habilitation in Pathophysiology and Experimental Pneumology, Justus Liebig University Giessen, 2005, Gießen, Germany

Supplementary Career Information

Periods	Details
1993 - 2003	Research fellow in the Clinical Research Group "Respiratory Insufficiency", Department of Medicine, Justus Liebig University Giessen
2003 - 2005	Research Assistant (C1), Department of Internal Medicine, Justus Liebig University Giessen
2006 - 2011	Honorary Professor for Pathophysiology and Experimental Pneumology, Justus Liebig University Giessen
2008 - 2011	Research group leader "Lung Vascular Remodeling and Anti-Remodeling", Max Planck Institute for Heart and Lung Research Bad Nauheim
Since 2011	Professor for Pulmonary Pharmacotherapy, Universities of Giessen and Marburg Lung Center (UGMLC), Justus Liebig University Giessen

Activities in the Research System *optional, free text***Supervision of Researchers in Early Career Phases** *optional, free text***Scientific Results****h-index 98, >67000 citations**

10 selected manuscripts:

1. Jafari L, Wiedenroth CB, Kriechbaum SD, Grün D, Chelladurai P, Guenther S, Kuenne C, Späth AM, Cherian AV, Troidl C, Wilhelm J, Keranov S, Keller T, Kojonazarov B, **Schermuly RT**, Guth S, Dörr O, Nef H, Boehm M, Spiekerkoetter E, Leszek P, Varga ZV, Ferdinandy P, Ghofrani HA, Dorfmueller P, Weißmann N, Hamm CW, Mayer E, Seeger W, Liebetrau C, Pullamsetti SS. Transcriptional changes of the extracellular matrix in chronic thromboembolic pulmonary hypertension govern right ventricle remodeling and recovery. *Nat Cardiovasc Res*. 2025 Jul;4(7):857-875. doi: 10.1038/s44161-025-00672-8.
2. Berrebeh N, Mbouamboua Y, Thuillet R, Ottaviani M, Robert F, Kamel Chelgham M, Magnone V, Desroches-Castan A, Ricard N, Anegon I, Remy S, **Schermuly RT**, Lebrigand K, Kojonazarov B, Savale L, Humbert M, Bailly S, Barbry P, Tu L, Guignabert C. Bone morphogenetic protein-9 controls pulmonary vascular growth and remodeling. *Proc Natl Acad Sci U S A*. 2025 Jul;122(26):e2410229122.
3. Guignabert C, Aman J, Bonnet S, Dorfmueller P, Olschewski AJ, Pullamsetti S, Rabinovitch M, **Schermuly RT**, Humbert M, Stenmark KR. Pathology and pathobiology of pulmonary hypertension: current insights and future directions. *Eur Respir J*. 2024 Oct 31;64(4):2401095.
4. Jurida L, Werner S, Knapp F, Niemann B, Li L, Grün D, Wirth S, Weber A, Beuerlein K, Liebetrau C, Wiedenroth CB, Guth S, Kojonazarov B, Jafari L, Weissmann N, Günther S, Braun T, Bartkuhn M, **Schermuly RT**, Dorfmueller P, Yin X, Mayr M, Schmitz ML, Czech L, Schlüter KD, Schulz R, Rohrbach S, Kracht M. A common gene signature of the right ventricle in failing rat and human hearts. *Nat Cardiovasc Res*. 2024 Jul;3(7):819-840.
5. Knight H, Abis G, Kaur M, Green HLH, Krasemann S, Hartmann K, Lynham S, Clark J, Zhao L, Ruppert C, Weiss A, **Schermuly RT**, Eaton P, Rudyk O. Cyclin D-CDK4 Disulfide Bond Attenuates Pulmonary Vascular Cell Proliferation. *Circ Res*. 2023 Dec 8;133(12):966-988.
6. Nayakanti SR, Friedrich A, Sarode P, Jafari L, Maroli G, Boehm M, Bourgeois A, Grobs Y, Khassafi F, Kuenne C, Guenther S, Dabral S, Wilhelm J, Weiss A, Wietelmann A, Kojonazarov B, Janssen W, Looso M, de Man F, Provencher S, Tello K, Seeger W, Bonnet S, Savai R, **Schermuly RT**, Pullamsetti SS. Targeting Wnt- β -Catenin-FOSL Signaling Ameliorates Right Ventricular Remodeling. *Circ Res*. 2023 May 26;132(11):1468-1485.
7. Berghausen EM, Janssen W, Vantler M, Gnatzy-Feik LL, Krause M, Behringer A, Joseph C, Zierden M, Freyhaus HT, Klinke A, Baldus S, Alcazar MA, Savai R, Pullamsetti SS, Wong DW, Boor P, Zhao JJ, **Schermuly RT**, Rosenkranz S. Disrupted PI3K subunit p110 α signaling protects against pulmonary hypertension and reverses established disease in rodents. *J Clin Invest*. 2021 Oct 1;131(19):e136939.
8. Seimetz M, Sommer N, Bednorz M, Pak O, Veith C, Hadzic S, Gredic M, Parajuli N, Kojonazarov B, Kraut S, Wilhelm J, Knoepp F, Henneke I, Pichl A, Kanbagli ZI, Scheibe S, Fysikopoulos A, Wu CY, Klepetko W, Jaksch P, Eichstaedt C, Grünig E, Hinderhofer K, Geiszt M, Müller N, Rezende F, Buchmann G, Wittig I, Hecker M, Hecker A, Padberg W, Dorfmueller P, Gattenlöhner S, Vogelmeier CF, Günther A, Karnati S, Baumgart-Vogt E, **Schermuly RT**,

Ghofrani HA, Seeger W, Schröder K, Grimminger F, Brandes RP, Weissmann N. NADPH oxidase subunit NOXO1 is a target for emphysema treatment in COPD. *Nat Metab.* 2020 Jun;2(6):532-546.

9. Weiss A, Neubauer MC, Yerabolu D, Kojonazarov B, Schlueter BC, Neubert L, Jonigk D, Baal N, Ruppert C, Dorfmueller P, Pullamsetti SS, Weissmann N, Ghofrani HA, Grimminger F, Seeger W, **Schermuly RT**. Targeting cyclin-dependent kinases for the treatment of pulmonary arterial hypertension. *Nat Commun.* 2019 May 17;10(1):2204.

10. Pullamsetti SS, Kojonazarov B, Storn S, Gall H, Salazar Y, Wolf J, Weigert A, El-Nikhely N, Ghofrani HA, Krombach GA, Fink L, Gattenlöhner S, Rapp UR, **Schermuly RT**, Grimminger F, Seeger W, Savai R. Lung cancer-associated pulmonary hypertension: Role of microenvironmental inflammation based on tumor cell-immune cell cross-talk. *Sci Transl Med* 2017,9(416).

Data protection and consent to the processing of optional data

If you provide voluntary information (marked as optional) in this CV, your consent is required. Please confirm your consent by checking the box below.

I expressly consent to the processing of the voluntary (optional) information, including “special categories of personal data”¹ in connection with the DFG’s review and decision-making process regarding my proposal. This also includes forwarding my data to the external reviewers, committee members and, where applicable, foreign partner organisations who are involved in the decision-making process. To the extent that these recipients are located in a third country (outside the European Economic Area), I additionally consent to them being granted access to my data for the above-mentioned purposes, even though a level of data protection comparable to EU law may not be guaranteed. For this reason, compliance with the data protection principles of EU law is not guaranteed in such cases. In this respect, there may be a violation of my fundamental rights and freedoms and resulting damages. This may make it more difficult for me to assert my rights under the General Data Protection Regulation (e.g. information, rectification, erasure, compensation) and, if necessary, to enforce these rights with the help of authorities or in court.

I may **revoke** my consent in whole or in part at any time – with effect for the future, freely and without giving reasons – vis-à-vis the DFG (postmaster@dfg.de). The lawfulness of the processing carried out up to that point remains unaffected. Insofar as I transmit “special categories of personal data” relating to third parties, I confirm that the necessary legitimation under data protection law exists (e.g. based on consent).

I have taken note of the DFG’s Data Protection Notice relating to research funding, which I can access at www.dfg.de/privacy_policy and I will forward it to such persons whose data the DFG processes as a result of being mentioned in this CV.

¹ Special categories of personal data are those “revealing racial or ethnic origin, political opinions, religious or philosophical beliefs, or trade union membership, and (...) genetic data, biometric data for the purpose of uniquely identifying a natural person, data concerning health or data concerning a natural person’s sex life or sexual orientation” (Article 9(1) GDPR).